Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029
Page: 104
Published Date: 07 Aug 2023
Category: Pharma & Healthcare
PDF Download
Get FREE Sample
Customize Request
-
Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags
Description
According to our (Global Info Research) latest study, the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market size was valued at USD 2887.2 million in 2022 and is forecast to a readjusted size of USD 16370 million by 2029 with a CAGR of 28.1% during review period.
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
The CAR T-cell-based drug market is driven by the growing demand for innovative and targeted cancer therapies. Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary approach that involves genetically modifying a patient's T cells to recognize and attack cancer cells. The success of CAR T-cell therapies in treating certain types of blood cancers, such as leukemia and lymphoma, has fueled market growth and encouraged research into expanding the application of CAR T-cell therapy to other solid tumor malignancies. However, the market also faces challenges, including the high cost of CAR T-cell therapy and the complexity of the manufacturing process, which may limit patient access. Additionally, the potential for severe side effects and the need for patient selection and management pose regulatory and clinical challenges. To succeed, companies must focus on advancing research, streamlining the production process, collaborating with healthcare providers to improve patient access and support, and addressing safety and efficacy concerns to establish CAR T-cell-based drugs as a transformative treatment option for cancer patients.
The Global Info Research report includes an overview of the development of the Chimeric Antigen Receptor (CAR) T-Cell Therapy industry chain, the market status of Lymphoma (CD19-targeted, BCMA-targeted), Multiple Myeloma (CD19-targeted, BCMA-targeted), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Regionally, the report analyzes the Chimeric Antigen Receptor (CAR) T-Cell Therapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Chimeric Antigen Receptor (CAR) T-Cell Therapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Chimeric Antigen Receptor (CAR) T-Cell Therapy industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., CD19-targeted, BCMA-targeted).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Chimeric Antigen Receptor (CAR) T-Cell Therapy market.
Regional Analysis: The report involves examining the Chimeric Antigen Receptor (CAR) T-Cell Therapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Chimeric Antigen Receptor (CAR) T-Cell Therapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Chimeric Antigen Receptor (CAR) T-Cell Therapy:
Company Analysis: Report covers individual Chimeric Antigen Receptor (CAR) T-Cell Therapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Chimeric Antigen Receptor (CAR) T-Cell Therapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lymphoma, Multiple Myeloma).
Technology Analysis: Report covers specific technologies relevant to Chimeric Antigen Receptor (CAR) T-Cell Therapy. It assesses the current state, advancements, and potential future developments in Chimeric Antigen Receptor (CAR) T-Cell Therapy areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Chimeric Antigen Receptor (CAR) T-Cell Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
CD19-targeted
BCMA-targeted
Market segment by Application
Lymphoma
Multiple Myeloma
Market segment by players, this report covers
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Chimeric Antigen Receptor (CAR) T-Cell Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Chimeric Antigen Receptor (CAR) T-Cell Therapy, with revenue, gross margin and global market share of Chimeric Antigen Receptor (CAR) T-Cell Therapy from 2018 to 2023.
Chapter 3, the Chimeric Antigen Receptor (CAR) T-Cell Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Chimeric Antigen Receptor (CAR) T-Cell Therapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Chapter 13, to describe Chimeric Antigen Receptor (CAR) T-Cell Therapy research findings and conclusion.
Table of Contents
1 Market Overview
1.1 Product Overview and Scope of Chimeric Antigen Receptor (CAR) T-Cell Therapy
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Chimeric Antigen Receptor (CAR) T-Cell Therapy by Type
1.3.1 Overview: Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Type in 2022
1.3.3 CD19-targeted
1.3.4 BCMA-targeted
1.4 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market by Application
1.4.1 Overview: Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Lymphoma
1.4.3 Multiple Myeloma
1.5 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size & Forecast
1.6 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast by Region
1.6.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region, (2018-2029)
1.6.3 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Prospect (2018-2029)
1.6.4 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Prospect (2018-2029)
1.6.6 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Prospect (2018-2029)
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.1.4 Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Novartis Recent Developments and Future Plans
2.2 Gilead Sciences
2.2.1 Gilead Sciences Details
2.2.2 Gilead Sciences Major Business
2.2.3 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.2.4 Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Gilead Sciences Recent Developments and Future Plans
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business
2.3.3 Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.3.4 Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.4 J & J
2.4.1 J & J Details
2.4.2 J & J Major Business
2.4.3 J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.4.4 J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 J & J Recent Developments and Future Plans
2.5 JW Therapeutics
2.5.1 JW Therapeutics Details
2.5.2 JW Therapeutics Major Business
2.5.3 JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.5.4 JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 JW Therapeutics Recent Developments and Future Plans
2.6 FOSUNKite
2.6.1 FOSUNKite Details
2.6.2 FOSUNKite Major Business
2.6.3 FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.6.4 FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 FOSUNKite Recent Developments and Future Plans
2.7 CARsgen Therapeutics
2.7.1 CARsgen Therapeutics Details
2.7.2 CARsgen Therapeutics Major Business
2.7.3 CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.7.4 CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 CARsgen Therapeutics Recent Developments and Future Plans
2.8 Autolus Therapeutics
2.8.1 Autolus Therapeutics Details
2.8.2 Autolus Therapeutics Major Business
2.8.3 Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.8.4 Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Autolus Therapeutics Recent Developments and Future Plans
2.9 Sorrento Therapeutics
2.9.1 Sorrento Therapeutics Details
2.9.2 Sorrento Therapeutics Major Business
2.9.3 Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.9.4 Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Sorrento Therapeutics Recent Developments and Future Plans
2.10 Mustang Bio
2.10.1 Mustang Bio Details
2.10.2 Mustang Bio Major Business
2.10.3 Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.10.4 Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Mustang Bio Recent Developments and Future Plans
2.11 Bluebird Bio
2.11.1 Bluebird Bio Details
2.11.2 Bluebird Bio Major Business
2.11.3 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.11.4 Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Bluebird Bio Recent Developments and Future Plans
2.12 Cellectis
2.12.1 Cellectis Details
2.12.2 Cellectis Major Business
2.12.3 Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.12.4 Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Cellectis Recent Developments and Future Plans
2.13 Allogene Therapeutics
2.13.1 Allogene Therapeutics Details
2.13.2 Allogene Therapeutics Major Business
2.13.3 Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.13.4 Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Allogene Therapeutics Recent Developments and Future Plans
2.14 Celyad
2.14.1 Celyad Details
2.14.2 Celyad Major Business
2.14.3 Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
2.14.4 Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Celyad Recent Developments and Future Plans
3.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Chimeric Antigen Receptor (CAR) T-Cell Therapy by Company Revenue
3.2.2 Top 3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Players Market Share in 2022
3.2.3 Top 6 Chimeric Antigen Receptor (CAR) T-Cell Therapy Players Market Share in 2022
3.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Overall Company Footprint Analysis
3.3.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Region Footprint
3.3.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Company Product Type Footprint
3.3.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value and Market Share by Type (2018-2023)
4.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Forecast by Type (2024-2029)
5.1 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Application (2018-2023)
5.2 Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Forecast by Application (2024-2029)
6.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2029)
6.2 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2029)
6.3 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country
6.3.1 North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2018-2029)
6.3.2 United States Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
6.3.3 Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
6.3.4 Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
7.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2029)
7.2 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2029)
7.3 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country
7.3.1 Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2018-2029)
7.3.2 Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
7.3.3 France Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
7.3.5 Russia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
7.3.6 Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
8.1 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Region
8.3.1 Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Region (2018-2029)
8.3.2 China Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
8.3.3 Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
8.3.4 South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
8.3.5 India Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
8.3.7 Australia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
9.1 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2029)
9.2 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2029)
9.3 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country
9.3.1 South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2018-2029)
9.3.2 Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
9.3.3 Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
10.1 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size by Country
10.3.1 Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2018-2029)
10.3.2 Turkey Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
10.3.4 UAE Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Size and Forecast (2018-2029)
11.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Drivers
11.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Restraints
11.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12.1 Chimeric Antigen Receptor (CAR) T-Cell Therapy Industry Chain
12.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy Upstream Analysis
12.3 Chimeric Antigen Receptor (CAR) T-Cell Therapy Midstream Analysis
12.4 Chimeric Antigen Receptor (CAR) T-Cell Therapy Downstream Analysis
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table of Figures
List of Tables
Table 1. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Novartis Company Information, Head Office, and Major Competitors
Table 6. Novartis Major Business
Table 7. Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 8. Novartis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Novartis Recent Developments and Future Plans
Table 10. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 11. Gilead Sciences Major Business
Table 12. Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 13. Gilead Sciences Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Gilead Sciences Recent Developments and Future Plans
Table 15. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 16. Bristol-Myers Squibb Major Business
Table 17. Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 18. Bristol-Myers Squibb Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Bristol-Myers Squibb Recent Developments and Future Plans
Table 20. J & J Company Information, Head Office, and Major Competitors
Table 21. J & J Major Business
Table 22. J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 23. J & J Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. J & J Recent Developments and Future Plans
Table 25. JW Therapeutics Company Information, Head Office, and Major Competitors
Table 26. JW Therapeutics Major Business
Table 27. JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 28. JW Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. JW Therapeutics Recent Developments and Future Plans
Table 30. FOSUNKite Company Information, Head Office, and Major Competitors
Table 31. FOSUNKite Major Business
Table 32. FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 33. FOSUNKite Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. FOSUNKite Recent Developments and Future Plans
Table 35. CARsgen Therapeutics Company Information, Head Office, and Major Competitors
Table 36. CARsgen Therapeutics Major Business
Table 37. CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 38. CARsgen Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. CARsgen Therapeutics Recent Developments and Future Plans
Table 40. Autolus Therapeutics Company Information, Head Office, and Major Competitors
Table 41. Autolus Therapeutics Major Business
Table 42. Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 43. Autolus Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Autolus Therapeutics Recent Developments and Future Plans
Table 45. Sorrento Therapeutics Company Information, Head Office, and Major Competitors
Table 46. Sorrento Therapeutics Major Business
Table 47. Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 48. Sorrento Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Sorrento Therapeutics Recent Developments and Future Plans
Table 50. Mustang Bio Company Information, Head Office, and Major Competitors
Table 51. Mustang Bio Major Business
Table 52. Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 53. Mustang Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Mustang Bio Recent Developments and Future Plans
Table 55. Bluebird Bio Company Information, Head Office, and Major Competitors
Table 56. Bluebird Bio Major Business
Table 57. Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 58. Bluebird Bio Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Bluebird Bio Recent Developments and Future Plans
Table 60. Cellectis Company Information, Head Office, and Major Competitors
Table 61. Cellectis Major Business
Table 62. Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 63. Cellectis Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Cellectis Recent Developments and Future Plans
Table 65. Allogene Therapeutics Company Information, Head Office, and Major Competitors
Table 66. Allogene Therapeutics Major Business
Table 67. Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 68. Allogene Therapeutics Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. Allogene Therapeutics Recent Developments and Future Plans
Table 70. Celyad Company Information, Head Office, and Major Competitors
Table 71. Celyad Major Business
Table 72. Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Product and Solutions
Table 73. Celyad Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Celyad Recent Developments and Future Plans
Table 75. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue (USD Million) by Players (2018-2023)
Table 76. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Share by Players (2018-2023)
Table 77. Breakdown of Chimeric Antigen Receptor (CAR) T-Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3)
Table 78. Market Position of Players in Chimeric Antigen Receptor (CAR) T-Cell Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 79. Head Office of Key Chimeric Antigen Receptor (CAR) T-Cell Therapy Players
Table 80. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Company Product Type Footprint
Table 81. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market: Company Product Application Footprint
Table 82. Chimeric Antigen Receptor (CAR) T-Cell Therapy New Market Entrants and Barriers to Market Entry
Table 83. Chimeric Antigen Receptor (CAR) T-Cell Therapy Mergers, Acquisition, Agreements, and Collaborations
Table 84. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (USD Million) by Type (2018-2023)
Table 85. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Share by Type (2018-2023)
Table 86. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Forecast by Type (2024-2029)
Table 87. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2023)
Table 88. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Forecast by Application (2024-2029)
Table 89. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 90. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 91. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 92. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 93. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 94. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 95. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 96. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 97. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 98. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 99. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 100. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 101. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 102. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 103. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 104. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 105. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Region (2018-2023) & (USD Million)
Table 106. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Region (2024-2029) & (USD Million)
Table 107. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 108. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 109. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 110. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 111. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 112. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 113. Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2018-2023) & (USD Million)
Table 114. Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type (2024-2029) & (USD Million)
Table 115. Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2018-2023) & (USD Million)
Table 116. Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Application (2024-2029) & (USD Million)
Table 117. Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2018-2023) & (USD Million)
Table 118. Middle East & Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Country (2024-2029) & (USD Million)
Table 119. Chimeric Antigen Receptor (CAR) T-Cell Therapy Raw Material
Table 120. Key Suppliers of Chimeric Antigen Receptor (CAR) T-Cell Therapy Raw Materials
List of Figures
Figure 1. Chimeric Antigen Receptor (CAR) T-Cell Therapy Picture
Figure 2. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Type in 2022
Figure 4. CD19-targeted
Figure 5. BCMA-targeted
Figure 6. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Application in 2022
Figure 8. Lymphoma Picture
Figure 9. Multiple Myeloma Picture
Figure 10. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Market Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 13. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Region (2018-2029)
Figure 14. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Region in 2022
Figure 15. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 16. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 17. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 18. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 19. Middle East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 20. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Revenue Share by Players in 2022
Figure 21. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 22. Global Top 3 Players Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share in 2022
Figure 23. Global Top 6 Players Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share in 2022
Figure 24. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Share by Type (2018-2023)
Figure 25. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share Forecast by Type (2024-2029)
Figure 26. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Share by Application (2018-2023)
Figure 27. Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Share Forecast by Application (2024-2029)
Figure 28. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 29. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 30. North America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Country (2018-2029)
Figure 31. United States Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 32. Canada Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 33. Mexico Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 34. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 35. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 36. Europe Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Country (2018-2029)
Figure 37. Germany Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 38. France Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 39. United Kingdom Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 40. Russia Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 41. Italy Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 42. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 43. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 44. Asia-Pacific Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Region (2018-2029)
Figure 45. China Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 46. Japan Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 47. South Korea Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 48. India Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 49. Southeast Asia Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 50. Australia Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 51. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 52. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 53. South America Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Country (2018-2029)
Figure 54. Brazil Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 55. Argentina Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 56. Middle East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Type (2018-2029)
Figure 57. Middle East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Application (2018-2029)
Figure 58. Middle East and Africa Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value Market Share by Country (2018-2029)
Figure 59. Turkey Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 60. Saudi Arabia Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 61. UAE Chimeric Antigen Receptor (CAR) T-Cell Therapy Consumption Value (2018-2029) & (USD Million)
Figure 62. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Drivers
Figure 63. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Restraints
Figure 64. Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Chimeric Antigen Receptor (CAR) T-Cell Therapy in 2022
Figure 67. Manufacturing Process Analysis of Chimeric Antigen Receptor (CAR) T-Cell Therapy
Figure 68. Chimeric Antigen Receptor (CAR) T-Cell Therapy Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
Research Methodology
Client Requirements
Review and analyze client requirements
Discussion of all the project requirements and queries
Flexibility Check
Project Feasibility Analysis
Finalizing tentative research programme
Structuring project proposal with scope, timeline, and costs
Analyzing Market Dynamics
Determination of key drivers, restraints, challenge, and opportunity
Identifies market needs and trends
Market Size Estimation & Forecast
Estimation of historical data based on secondary and primary data
Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)
Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies
Consideration of geography, region-specific product/service demand for region segments
Consideration of product utilization rates, product demand outlook for segments by application or end-user.
Data Source
Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports,
paid database, press releases, blogs, newsletters,and GIR repositories.
Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts
to verify insights.
Validation
and
triangulation of
secondary and primary source.
Collection of data
Cumulating and collating the essential qualitative and quantitative data
Generation of report in client requested format by research analysts
Reviews by expert analysts
Final quality check
Clarifying queries
Receiving feedback
Ensuring satisfaction
01 Identification of data
This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
-
02 Evaluation of Market Dynamic
This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
-
03 Collection of Data
This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
-
04 Collaboration of Data
This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis
This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.
Companies Mentioned
Novartis Gilead Sciences Bristol-Myers Squibb J & J JW Therapeutics FOSUNKite CARsgen Therapeutics Autolus Therapeutics Sorrento Therapeutics Mustang Bio Bluebird Bio Cellectis Allogene Therapeutics Celyad
Related Reports
07 Aug 2023
Pharma & Healthcare
Purchase Options
Add To Cart
Buy Now
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>
